Clinical Research Directory

Inclusion Criteria: \- 1. Adults aged 18 years or older. 2. Voluntarily provide written informed consent before participation. 3. Patients with an indeterminate renal mass, suspected renal cell carcinoma, previously diagnosed clear cell renal cell carcinoma, or suspected recurrent renal cell carcinoma based on clinical or imaging findings. 4\. Estimated life expectancy of at least 6 months. 5. Participants of childbearing potential must use appropriate and highly effective contraception for at least 35 days after administration of the study tracer. Exclusion Criteria: * 1\. Renal tumor known to represent metastasis from another primary malignancy. 2. Other active malignancies requiring treatment. 3. Chemotherapy, radiotherapy, or immunotherapy within 4 weeks before study enrollment. 4\. Renal dysfunction with an estimated glomerular filtration rate (eGFR) ≤60 mL/min/1.73 m². 5\. Uncontrolled psychiatric disorders that may interfere with study participation. 6\. Pregnancy or breastfeeding. 7. Severe nonmalignant diseases, including infectious, autoimmune, or metabolic diseases, that in the investigator's opinion may interfere with the study objectives, participant safety, or study compliance. 8\. Individuals belonging to vulnerable populations.